A Clinical Audit Report on Compliance to Hepatitis B Vaccination in Type 2 Diabetes Mellitus Patients in a Primary Health Care Centre in Qatar

Maxwell Sleiman*, Moqthiar Sharief, Muhammad Atif Waheed, Ahmed Rashid Shaik and Shawqiya Almajid

Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar

ABSTRACT

Objective: Numerous infectious diseases can be prevented in adults through a “lifetime vaccination strategy.” The burden of hepatitis B disease was found to be greater in diabetic patients. Since 2011, the American Advisory Committee on Immunization Practices has recommended that diabetic patients be vaccinated against hepatitis B. Patients with diabetes mellitus are at an increased risk of contracting hepatitis B virus infection and its complications.

Aim: The purpose of this study was to determine compliance with the audit criterion for hepatitis B vaccination among diabetic patients and to recommend changes in practice to improve hepatitis B vaccination coverage among type 2 diabetes mellitus patients under the age of 60.

Methodology: A random sample of 50 patients with Type 2 Diabetes Mellitus aged less than 60 years who presented to Umm Ghuwailina Health Centre (UMG-HC) during the study period will be evaluated for hepatitis B vaccination records during the audit period, which runs from August 1st to October 31st, 2019.

Results: Only 8% (6.8% men and 9.5% women) in the audit group had received hepatitis B vaccine. Hepatitis B vaccination coverage was found to be low in patients with diabetes mellitus, indicating their vulnerability to this deadly disease.

Conclusion: Hepatitis B vaccination coverage was extremely low among a randomly selected diabetic population in a primary health care centre in Qatar. This may increase the risk of infection with hepatitis B in this population. In patients with diabetes, the hepatitis B vaccine is immunogenic and has a similar safety profile to vaccination in healthy controls. Due to the fact that increasing age is generally associated with a decline in seroprotection rates, the hepatitis B vaccine should be administered as soon as possible following diabetes diagnosis. Much work is required to raise awareness among health care providers and diabetic patients about the importance of hepatitis B vaccination.

KEYWORDS: Clinical trial; Infections; DM; Infectious diseases

INTRODUCTION

Infectious viral hepatitis is a significant threat to global health. Hepatitis A and E viruses (HAV and HEV) are endemic in a large number of low-income countries [1]. They typically cause self-limiting hepatitis but can occasionally result in fulminant liver failure and, in extremely rare cases of immunosuppression, chronic HEV infection. Hepatitis B and C viruses both cause acute illness but are more frequently associated with progressive liver fibrosis, cirrhosis, and an increased risk of liver cancer (specifically hepatocellular carcinoma) [1]. Hepatitis B infection is a significant global public health problem because it is extremely prevalent throughout much of the world and frequently results in chronic infection, cirrhosis, and liver cancer. Globally, the prevalence of chronic carriage varies between 0.1 and over 20% [2]. Around 15%-

Quick Response Code: Address for correspondence: Maxwell Sleiman, Primary Health Care Corporation (PHCC), Doha, P.O. Box 26555, Qatar

Received: November 08, 2021 Reviewed: December 05, 2021 Published: December 30, 2021

How to cite this article: Sleiman M, Sharief M, Waheed MA, Shaik AR, Almajid S. A Clinical Audit Report on Compliance to Hepatitis B Vaccination in Type 2 Diabetes Mellitus Patients in a Primary Health Care Centre in Qatar. 2021- 3(6) OAJBS.ID.000368. DOI: 10.38125/OAJBS.000368
Hepatitis B Virus infection is uncommon (less than 2%) and of early childhood viral infection exposure [12]. The infection rate is approximately 10%-60% in and Japan all have intermediate endemic zones for Hepatitis B from one child to another (congenital transmission) (horizontal from an infected mother to her infant (perinatal transmission) or point, and infections frequently occur during childhood, either 

The majority of infections in infants and children are asymptomatic, whereas adults have a 30% chance of developing symptomatic acute hepatitis B [7].

The prevalence of chronic Hepatitis B Virus infection varies dramatically across geographies and populations, ranging from 0.1 to 35% at the national level [8]. Hepatitis B Virus endemicity is classified into four (formerly three) levels: low (2%), lower intermediate (2.4-9%), higher intermediate (5-7.9%), and high (8%) endemicity [8]. Males, on average, have a significantly higher prevalence [9].

Around 60% of the world’s population lives in areas with a high prevalence of chronic Hepatitis B Virus [10]. Asia, Sub-Saharan Africa, the Pacific, parts of the Amazon Basin, the Middle East, Central Asian Republics, the Indian subcontinent, and a few countries in Central and Eastern Europe are among the areas where Hepatitis B Virus is highly endemic [11]. In these parts of the world, up to 70%-90% of the population has been infected at some point, and infections frequently occur during childhood, either from an infected mother to her infant (perinatal transmission) or from one child to another (congenital transmission) (horizontal transmission).

The Middle East, Eastern and Southern Europe, South America, and Japan all have intermediate endemic zones for Hepatitis B Virus infection. The infection rate is approximately 10%-60% in these populations, and the chronic carrier rate is approximately 2%-7%. Epidemiologically, infection occurs in both children and adults. Chronic infections are more prevalent in infants as a result of early childhood viral infection exposure [12].

A low prevalence is observed in western and northern Europe, North America, Central America, and the Caribbean, where chronic Hepatitis B Virus infection is uncommon (less than 2%) and primarily acquired during adulthood [13].

Comorbidities such as diabetes mellitus may increase the risk of Hepatitis B Virus infection. In the United States (US), patients with diabetes mellitus (DM) are twice as likely as healthy adults to develop acute hepatitis B virus infections [14]. Additionally, the seroprevalence of antibodies to the Hepatitis B Virus core antigen is 60% higher in patients with diabetes mellitus than in those without diabetes mellitus [15]. Numerous Hepatitis B Virus outbreaks among patients with diabetes mellitus have been reported in the United States and several European countries [16,17]. 25 of the 29 outbreaks reported in long-term care or assisted living facilities in the United States since 1996 involved assisted blood glucose monitoring [15].

At the end of 2011, the US Advisory Committee on Immunization Practices recommended hepatitis B vaccination for adults with diabetes aged 19 to 59 years and at the discretion of the treating clinician for diabetic adults aged 60 years [15]. Similar recommendations have been made in other countries, including Canada and the Czech Republic, and have been adopted by Belgium’s Superior Council of Health [18,19]. Seroprotection rates following hepatitis B vaccination appear to be lower in adults with diabetes mellitus (DM) or renal disease [20-22].

Thus, the aim of this study was (i) to access the compliance to hepatitis B vaccination in type 2 diabetes mellitus patients in Qatar by conducting an audit report on this behalf and (ii) to provide recommendation of getting the Hepatitis B Virus in the diabetic population.

**METHODOLOGY**

**Population**

This was a retrospective study where we reviewed the healthcare records of randomly selected 50 patients with Type 2 Diabetes Mellitus aged between 19 and 60 who presented to Umm Ghuwailina Health Centre (UMG-HC) for their Hepatitis B vaccination records. The study occurred between August 1st, 2019, and October 30th, 2019.

**Data Collection**

Random selection of 50 patients with Type 2 Diabetes Mellitus aged less than 60 years old who presented to UMG-HC during the study period was evaluated for Hepatitis B vaccination records during the audit period, i.e., between August 1st, 2019, and October 31st, 2019. The patients’ health records were evaluated for Hepatitis B vaccination. This audit was undertaken to evaluate compliance with the hepatitis B vaccination protocol for patients with diabetes under age 60 and suggest recommendations to improve the uptake rate of hepatitis B vaccination in Type 2 Diabetes Mellitus patients in UMG-HC.

**Ethical Approval**

Ethical approval was not required as per the retrospective aspect of the present study. However, the audit was approved by the Primary Health Care Corporation (PHCC) under the reference (HC/CA.20.001).

**Management of Type 2 Diabetic Patients in Qatar**

The average outpatient visit for an adult patient with diabetes involves numerous interventions and discussions, including management of multiple medications; assessment of control of glycemia, blood pressure, and dyslipidemia; counselling regarding diet and exercise; screening for diabetes complications; and often
assessment and management of other acute and chronic concerns.

Now clinicians have another intervention for many of their adult patients with diabetes: the vaccination series for hepatitis B virus.

According to the type 2 diabetes vaccination schedule in Qatar and the updated PHCC clinical practice guidelines for the management of type 2 diabetes in adults, it is recommended to:

Table 1: List of vaccines offered by the Primary Health Care Corporation (PHCC) which is the main governmental Primary Health care facility in Qatar.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Recommendation</th>
<th>Vaccine Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>All adults ≤ 60 years of age with diabetes Consider in those &gt;60 years of age with diabetes</td>
<td>3 doses at 0, 1, 6 months</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>All adults ≥ 65 years of age Adults &lt;65 years of age with diabetes</td>
<td>1 dose at ≥65 years or age 1 dose at &lt;65 years of age with 1 additional dose at ≥65 and ≥5 years from first dose</td>
</tr>
<tr>
<td>Influenza</td>
<td>All adults</td>
<td>1 dose annually 3 vaccine options (approved for):  • Traditional injected vaccine (any adult)  • Intradermal vaccine (adults 18-65 years)  • High dose injected vaccine (adults ≥65 years)</td>
</tr>
<tr>
<td>Td/Tdap</td>
<td>All adults</td>
<td>Td every 10 years with Tdap in place of one Td vaccine Certain adults should not wait 10 years to get Tdap:  • Pregnant women (late in trimester 2 or anytime in trimester 3)  • Those who anticipate close contact with infants &lt;1 year of age  • Healthcare workers</td>
</tr>
<tr>
<td>Shingles</td>
<td>All adults</td>
<td>1 dose at ≥60 years of age</td>
</tr>
<tr>
<td>HPV</td>
<td>All women up to age 26, unless immunized earlier All men up to age 21 (may be vaccinated up to age 26), unless immunized earlier</td>
<td>3 doses at 0, 2, 6 months</td>
</tr>
</tbody>
</table>

Td, tetanus and diphtheria: Tdap, tetanus, diphtheria, and pertussis. • Additional vaccines are recommended for adults who have certain risk factors or who were not immunized against certain diseases as children. Full recommendations are available at cdc.gov/vaccines.

RESULTS

A total of 50 health records of patients with type 2 diabetes mellitus were reviewed for evidence of hepatitis B vaccination. Key findings showed that the data revealed that amongst the 50 randomly selected patients, 29 (58%) men and 21 (42%) women. They were between the ages of 19 and 60. Sex distribution is presented in Figure 1 and age distribution is presented in Figure 2.

Amongst all the investigated patients, only 4/50 (8%: 6.8% men and 9.5% women) had documented evidence of hepatitis B vaccination in their respective health records (Figure 3).

Figure 1: Sex distribution of this investigated population.
Hepatitis B outbreaks among diabetic patients residing in long-term care settings (e.g., nursing homes and assisted-living facilities) suggest that these settings may pose an increased risk of Hepatitis B Virus infection [35]. However, the incidence and magnitude of risk for acute hepatitis B in the general population of adults with diabetes, after excluding individuals whose Hepatitis B Virus infection could reasonably be attributed to other recognized risk behaviors, are unknown.

Adults can currently choose from three Hepatitis B Virus vaccines: Engerix-B (20mg/mL) and Recombivax HB (10mg/mL) are both single-antigen vaccines that contain only antibodies against the hepatitis B surface. Twinrix (20mg/mL) is another option; it is a combination vaccine that contains antigens for both hepatitis A and B viruses [36].

Numerous studies on the prevalence of hepatitis B have produced inconsistent findings depending on age and region. According to the 2007 report of the hepatitis B consensus meeting, the average rate of HBsAg carriers in the Turkish population is 4-5% [37]. According to the World Health Organization, HBsAg positivity was estimated to be 1-2% in blood donors and 3-4% in the general population in Turkey in 2013, and a total of 1,834,600 people were estimated to be infected with hepatitis B in 2013 [38]. These findings suggest that hepatitis B prevalence has been declining in recent years, with the decline being more pronounced outside of endemic regions. The decrease in the general population can be attributed to a decrease in the prevalence of hepatitis B in children and adolescents following the inclusion of the hepatitis B vaccine in the paediatric immunization program in 1998 [39]. However, because these patients have not reached adulthood, the effects of hepatitis B vaccination on the adult population are not yet evident [40]. Additionally, no study has been conducted on vaccination rates in adults.

Diabetes patients had a higher prevalence of hepatitis B and hepatitis B-related hospitalizations [41]. Occult hepatitis B was significantly more prevalent in patients with type 2 diabetes than in the control group (11% vs 3%, respectively) [42]. Hepatitis B is a virus that can persist on surfaces for a long period of time [43]. In institutions, epidemics have been reported as a result of hepatitis B virus transmission via blood glucose monitoring devices and commonly used insulin pens [44]. Additionally, diabetic patients are known to have an increased susceptibility to infections due to abnormalities in their immune systems, which may contribute to their susceptibility to Hepatitis B Virus infections [45]. In patients with poor metabolic control, it is possible to observe impairment of T cell transformation, a decrease in the total number of T cells, and a specific decrease in the CD4 phenotype [46]. Serum immunoglobulin levels are also lower in diabetics than in healthy individuals. In individuals with prolonged type 1 diabetes who have received hepatitis B vaccination, the antibody response to hepatitis B antigens is weak. Impairment in humoral and cellular immune responses can be attributed in part to an inability to recognize antigens [46]. As a result, the immune system abnormalities observed in patients with type 2 diabetes may play a role in the development of hepatitis B.

Prior to the publication of updated vaccination recommendations, surveillance studies revealed that the rate of hepatitis B vaccination was extremely low in diabetic patients. According to data from the United States of America, 19.5 percent of diabetic patients have received a single dose of hepatitis B vaccine, while only 16.6 percent have received all three recommended doses...
Another study published in Spain found that 4.2% of diabetic patients received vaccination [48]. The reasons for the low hepatitis B vaccination coverage among diabetics in our study could be attributed to physicians’ fundamental medical knowledge and attitudes; patients’ perceptions and attitudes toward vaccination; low health literacy; financial barriers, systemic limitations; and a lack of vaccine coverage data. Doctor-related barriers to vaccination include a lack of basic knowledge and current recommendations about adult vaccination, inconsistent assessment of vaccination status, and insufficient time spent communicating the benefits of the hepatitis B vaccine [49]. Recommendations that are not supported by public funding mechanisms may result in a decrease in vaccine uptake [50]. Other factors relating to the health care system, such as the absence of reminder-recall systems, immunization records, computerized vaccine registries, and vaccine delivery systems, may contribute to low vaccine coverage rates [51]. A review of the effectiveness of interventions to increase targeted vaccination coverage for influenza, pneumococcal, and hepatitis B vaccines concluded that the only strategy found to be effective when implemented alone was provider reminder systems [52]. Finally, at the national level, a country’s vaccination strategies may be harmed by a lack of surveillance data on vaccination coverage and documented vaccination recommendations [51].

According to the most recent data, the hepatitis B vaccine is cost-effective in diabetic patients aged 20–59 years [53]. Given the economic burden of chronic hepatitis, it would be appropriate to emphasize the importance of preventive measures and widespread hepatitis B vaccination in terms of both individual healthcare and national resources [54].

In conclusion, this preliminary study demonstrated that hepatitis B vaccination status and/or seroprevalence data should be verified at every encounter with diabetic patients in daily practice. Although our study population consisted of a randomly selected adult patient population in a primary health care setting, nearly 8% of patients had a history of hepatitis B vaccination, emphasizing the importance of maintaining a lifelong vaccination log and inquiring about vaccination data.

EXTENSION

In light of the global situation created by the emergence of COVID-19 and the likelihood of severe infection and complications for people living with comorbidities, we recommend tighter control over routine vaccinations such as the Hepatitis B vaccine for all people living with chronic health conditions such as diabetes.

 Globally, the COVID-19 pandemic has resulted in a dramatic loss of human life and poses an unprecedented public health challenge [55-70]. COVID-19 has been associated with a variety of complications, particularly in the diabetic population, and it has the potential to be fatal in many cases. Exposure to COVID-19 and hepatitis B may pose a serious threat to the diabetic population.

LIMITATIONS

The primary limitation of this study is the small sample size of 50 patients, which does not represent the entire population of Qatar, even if patient selection was random.

As a result, the findings of this study cannot be extrapolated to the entire Qatari population. Furthermore, this may be an underestimate given the number of patients excluded due to the random selection of patients. Our review of the literature revealed no study from Qatar that quantified the proportion of diabetic patients who are not vaccinated against hepatitis B, implying the need for hepatitis B vaccination. In this regard, we believe that this study provides critical preliminary findings for a country with a high diabetes prevalence.

CONCLUSION

According to the audit, only eight percent of the audit group had received hepatitis B vaccination. Hepatitis B vaccination coverage in patients with diabetes mellitus was found to be low, indicating their vulnerability to this serious and potentially fatal disease. The audit findings demonstrated that significant work remains to be done to raise awareness among health care providers and diabetic patients about the importance of hepatitis B vaccination uptake.

DECLARATIONS

Availability of Data and Material

All data analysed and reported in this study are available from the first author on reasonable request.

Consent to Participate

All participants provided informed consent before participating in the study.

Consent for Publication

All Physicians provided consent for anonymous data use for research purposes and publications. All authors approved of the final version to be published and agree to be accountable for any part of the work.

REFERENCES


